16.59

0.90% -0.15

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Why ACAD Down? Discussions Forecast

Acadia Pharmaceuticals Inc stock is currently priced at $16.59, with a 24-hour trading volume of 1.09M. It has seen a -0.90% decreased in the last 24 hours and a -7.58% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $16.86 pivot point. If it approaches the $16.48 support level, significant changes may occur.

Previous Close:

$16.74

Open:

$16.81

24h Volume:

1.09M

Market Cap:

$2.73B

Revenue:

$726.44M

Net Income/Loss:

$-61.29M

P/E Ratio:

-18.03

EPS:

-0.92

Net Cash Flow:

$-23.35M

1W Performance:

-3.49%

1M Performance:

-7.58%

6M Performance:

-27.81%

1Y Performance:

-17.63%

1D Range:

$16.55

$16.86

52W Range:

$16.55

$33.99

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

858-558-2871

Address

3611 Valley Centre Drive, Suite 300, San Diego

Employee

410

Twitter

@acadiapharma

Next Earnings Date

2024-05-08

Latest SEC Filings

ACAD's Discussions on Twitter

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

Zacks Investment Research

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

Zacks Investment Research

Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data

Acadia Pharmaceuticals Inc (ACAD) Revenue 2024

ACAD reported a revenue (TTM) of $726.44 million for the quarter ending December 31, 2023, a +40.45% rise year-over-year.

Acadia Pharmaceuticals Inc (ACAD) Net Income 2024

ACAD net income (TTM) was -$61.29 million for the quarter ending December 31, 2023, a +71.62% increase year-over-year.

Acadia Pharmaceuticals Inc (ACAD) Cash Flow 2024

ACAD recorded a free cash flow (TTM) of -$23.35 million for the quarter ending December 31, 2023, a +79.53% increase year-over-year.

Acadia Pharmaceuticals Inc (ACAD) Earnings per Share 2024

ACAD earnings per share (TTM) was -$0.38 for the quarter ending December 31, 2023, a +71.64% growth year-over-year.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.